quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake.

View original at finance.yahoo.com
This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake. Artificial intelligence (AI) stocks have been leading the market higher for the past few years, but investors hit the emergency brake in 2026, sending many tech stocks suddenly tumbling…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Micron is the best bargain among tech stocks after the rotation

    60% confidence
  • Long-term HBM contracts will raise the floor on the DRAM market and make it less cyclical

    60% confidence
  • Micron's stock looks like a buy after this dip due to the new floor and secular growth trends in AI infrastructure

    60% confidence
  • The move into value and small-cap stocks is not necessarily a bad move with great bargains in the space

    60% confidence
  • Micron issued robust guidance

    60% confidence
  • All three big DRAM makers are working to sign longer-term contracts for HBM of between three and five years with base volume commitments

    60% confidence
  • The current DRAM cycle does not look like an ordinary DRAM cycle due to HBM structural drivers

    60% confidence
  • Investors are clearly questioning Micron's earnings sustainability despite strong current performance

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
This Growth Stock Is Down 20% in the Great Rotation. I Think That's a Mistake. — Source | Via News | pt.VIA.NEWS